Phased 10-15% JNJ trim recommended; structural floor intact; reject full Sell escalation
The neutral analyst's phased framework is closest to correct but magnitudes are tightened from 35-45% to 10-15% combined (Tranche 1: ~5-7% at $266; Tranche 2: ~5-8% at $269-273), rejecting both the trader's full Sell escalation and the conservative analyst's deeper 50-60% benchmark weighting as repeating the 9/09 sizing mistake. The $278.43 stop is eliminated and reframed as a re-evaluation trigger. Structural support (200 SMA at $234.55, AAA credit, 62-year dividend streak, 29.2% margins) remains intact and has produced +1.1%, +2.3%, +2.7%, and +0.1% alpha in prior Underweight calls, capping trim magnitude at 10-15%.
| Position | Action |
|---|---|
| Tranche 1: ~5-7% trim | Sell at-or-near market at $266 |
| Tranche 2: ~5-8% trim | Pre-stage contingent sell orders at $269-273 |
| Re-entry Tranche 1 (50% of re-add) | Buy half at $240 zone with 50 SMA flattening/higher and MACD histogram no longer deepening |
| Re-entry Tranche 2 (remaining 50%) | Buy remaining half at $234 with confirmed higher low on daily chart |
JNJ's 4.3% pullback to the 50 SMA is a buyable entry in a structurally bullish trend, as reaccelerating revenue growth, imminent product catalysts (Icotyde China, MedTech cardiovascular), and best-in-class financial metrics (AAA rating, 0.235 beta, 29.2% operating margin) support a forward P/E that will look cheap once the Stelara LOE transition completes by mid-2027.
| Indicator | Value | Signal |
|---|---|---|
| close | $266.35 | neutral |
| close_10_ema | $269.72 | bearish |
| close_50_sma | $261.51 | bullish |
| close_200_sma | $234.55 | bullish |
| rsi | 50.14 | neutral |
| macd | 3.02 | bearish |
| macds | 3.87 | bearish |
| macdh | -0.85 | bearish |
| boll_mid | $268.74 | neutral |
| boll_ub | $278.74 | bearish |
| boll_lb | $258.75 | bullish |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Price at $234 + confirmed higher low on daily chart
Then: Re-add remaining half position at $234
↩ rebuts: “Bear 'Stelara LOE Cliff' thesis”
EV: ~1:2.5 risk/reward to prior swing high · concedes: International revenue exposure (~40%) creates mild FX headwind in strong dollar environments; Stock is trading at 96% of 52-week high, limiting near-term upside optionality
JNJ is a sell-into-strength opportunity at the top of a $641 billion cycle, as stretched valuations (PEG of 4.38, forward P/E of 21.64x), an unpriced $7B Stelara cliff, a risky $14.5B Caplyta acquisition creating negative tangible book value, multiple macro and technical headwinds, and a stock at 96% of its 52-week high offer no margin of safety for new buyers.
· concedes: Structural trend is not broken yet — which is exactly why you should let it break before you buy; Credit given to bull for at least mentioning the $14.5B Intra-Cellular deal; MACD is not a death cross 'at this stage'; The Texas Two-Step bankruptcy maneuver is 'one approach' to talc liability; The credit ratings still intact support the 'AAA fortress balance sheet' framing; The defensive nature of the business is real and acknowledged
→ vs neutral: Waiting for 'confirmed breakdown' below $258.75 means holding through a $7+ per share drawdown just to get 'permission' to trim—catching a falling knife with both hands rather than acting on leading indicators like the MACD crossing bearish
→ vs conservative: AAA rating and 62-year dividend streak are real but not a free pass to ignore valuation—the fundamentals report itself concludes risk/reward is 'less attractive than it was 6 months ago' and endorses re-add levels at $236-240, contradicting the hold-at-any-price thesis
| atr | 5.54 | neutral |
| vwma | $270.29 | bearish |
Support: 261.51 · 258.75 · 234.55 | Resistance: 278.43 · 269.72 · 268.74
The stock is in a chop zone with mixed signals: strong long-term bullish structure (price well above 200 SMA) conflicted by short-term bearish momentum (MACD bearish cross, price below 10 EMA, negative histogram at -0.85). RSI at 50.14 sits at the neutral midline, indicating neither overbought nor oversold conditions. The pullback from $278.43 has been orderly, testing the 50 SMA support at $261.51, with $258.75 (Bollinger lower band) as the critical breakdown level. VWMA at $270.29 above price suggests distribution rather than fresh accumulation. Recommended action is HOLD with a trailing stop near $258.75.
Market Cap
$641.88B
P/E (TTM)
30.86x
Forward P/E
21.64x
PEG Ratio
4.38
P/B
7.55x
Dividend Yield
2.01%
Beta
0.235
Revenue (TTM)
$97.93B
Gross Profit (TTM)
$66.73B
EBITDA (TTM)
$34.87B
Net Income (TTM)
$21.04B
EPS (TTM)
$8.63
Forward EPS
$12.31
Cash & ST Investments (Q2'26)
$20.76B
Total Debt (Q2'26)
$49.04B
Net Debt (Q2'26)
$28.61B
Stockholders' Equity (Q2'26)
$84.97B
Goodwill + Intangibles (Q2'26)
$96.71B
Current Ratio (Q2'26)
1.089
Free Cash Flow (TTM)
$16.89B
FCF Margin (TTM)
~17.2%
Gross Margin (TTM)
68.1%
Operating Margin
29.2%
Net Profit Margin
21.5%
ROE
25.7%
ROA
8.6%
Debt/Equity
0.58x
52-Week High
$281.07
52-Week Low
$173.33
50-Day MA
$262.23
200-Day MA
$236.49
Annual Dividend (FY25)
~$12.4B
Annual Buybacks (FY25)
$5.95B
Total Capital Returned (FY25)
~$18.3B
Revenue CAGR (FY22–FY25)
~5.6%
FCF CAGR (FY22–FY25)
~4.0%
Credit Rating
AAA
Strengths
Concerns
Fundamental Quality: A+ (Best-in-class). Valuation: B-/C+ (Elevated). Momentum: A (Strong uptrend, near 52W highs). Risk/Reward at Current Price: B (Favorable for patient long-term investors, less so for tactical buyers near highs). Johnson & Johnson remains one of the highest-quality, most-defensive equity investments in the global market with fortress-grade AAA balance sheet, reaccelerating revenue growth (~6.6% YoY in Q2'26), and reliable $16.89B FCF. However, the stock trades near 52-week highs with elevated multiples (P/E 30.86x, PEG 4.38x), and the Stelara LOE cliff in 2027 looms as the next major test for ~$7B+ in revenue at risk. A prudent stance would be to maintain or add on pullbacks toward the 200-day MA (~$236) rather than chase the current price.
Macro: Hawkish Fed regime with 93% probability of zero rate cuts in 2026 (up 4.2pp week-over-week) per Polymarket as of Sept 10, 2026. Very low US recession probability at 8%. Strong dollar environment typical of hawkish Fed is a mild FX headwind for JNJ's ~40% international revenue mix. T-bill yields at 5%+ make JNJ's ~3% dividend yield less attractive on a relative basis, but AAA credit rating and defensive characteristics compensate. Low recession odds support stable healthcare utilization and prescription volumes.